EPIS_B: Net sales grew, losses narrowed, and US market expansion accelerated, supported by new funding

About this update from Episurf Medical Ab Class B

Net sales rose to SEK 13.0m and operating loss narrowed to SEK -77.2m in 2024, driven by US expansion, cost reductions, and a SEK 90m rights issue. FDA review for a new big toe implant is ongoing, with further US growth and new product launches planned for 2025.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Episurf Medical Ab Class B